December 16, 2016 / 6:42 PM / 8 months ago

BRIEF-Celsion Corporation announces progress with Thermodox development efforts in China and Asia Pacific

Dec 16 (Reuters) - Celsion Corp :

* Expect to initiate additional sites for Phase III Optima trial in Vietnam in early 2017

* Recently met with China Food and Drug Administration (CFDA) to discuss ongoing Phase 3 Optima program and regulatory pathway for Thermodox in China

* CFDA informed Co if Phase 3 Optima trial is successful, trial could serve as basis for a direct regulatory filing in China

* Phase III Optima study is expected to enroll up to 550 patients at up to 75 clinical sites in U.S., Europe, China, Asia Pacific

* Celsion Corporation announces progress with Thermodox development efforts in China and Asia Pacific

* CFDA informed Co if Phase 3 trial is successful, trial could serve as basis for direct regulatory filing in China without need to file for prior approval in U.S. or European Union Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below